908 Devices Inc. (MASS)
Healthcare
- Fundamental
- 3
- Sentiment
- 2
- Technical
- 3
Do Nothing: qualitativeScore is 2 (below the required floor of 3) so no bullish entry is admissible; independently, the 20-day average dollar volume of $4,430,673 is below the $5,000,000 liquidity floor, and a confirmed Q3 2026 earnings date on 2026-11-09 sits inside the 15-trading-day holding window (horizon 2026-11-10).
Company overview
908 Devices Inc. develops handheld mass spectrometry and FTIR devices for health and safety applications. Its products include MX908, XplorIR, ThreatID, ProtectIR, and VipIR, which are used for rapid analysis and identification of chemical hazards. The company operates globally and is headquartered in Burlington, Massachusetts.
Fundamental
fair908 Devices shows revenue growth and solid liquidity, but profitability remains a challenge with negative margins.
908 Devices has solid liquidity (about $101.5M of cash and marketable securities at 2026-06-30 and a current ratio around 2.7) and the most recent filings show revenue momentum plus raised FY2026 guidance. Profitability remains the limiting factor: trailing net margin is roughly -57% and EBITDA is still negative, which makes earnings-based valuation metrics less useful and results in negative discounted-cash-flow outputs. Overall this reads as an execution-dependent growth story with improving fundamentals, best treated as a watchlist/turnaround until sustained operating leverage is visible in reported results and repeatable free cash flow.
Sentiment
weakSentiment is weak with no actionable catalysts and insider selling weighing on perception.
908 Devices has no actionable catalyst in the next 30 days — the rewarded but 70-day-old Q2 beat (2026-08-11, revenue +23%, raised 2026 outlook, announced) is fully digested, and the trailing 14 days produced only headline-only product blurbs plus a routine 10b5-1 CFO trading-plan sale. Media sentiment deteriorated determinately from a +0.20 baseline to −0.03 in the scoring window with no offsetting market-rewarded bullish element, while the Red-Flag Screen is clean and no cap was applied, leaving an Absent rather than mixed setup.
Technical
fairThe stock is pulling back within an uptrend, trading above key moving averages but below short-term resistance.
The chart is a short-term pullback inside a recovering intermediate uptrend, which scores a mixed 3/5. Price 11.51 sits above the rising SMA50 (10.93) and SMA200 (8.11) — the trend frame that matters for a dip-buy — but below the short-term stack: SMA20 11.86, EMA9 11.68, EMA21 11.57, WMA9 11.64 and DEMA14 11.80, so the immediate pullback is still in force. Momentum is neutral-to-fading: RSI14 51.06 sits at the midline, Williams %R −83.26 shows short-term oversold pressure, MACD line 0.24 remains positive but has rolled below its signal (0.39) with the histogram at −0.15, confirming the 2026-10-06 high (13.35) has not been reclaimed. ADX14 29.47 confirms a strong prevailing trend, and read with price above SMA50/200 it is an up-trend reading, not a down-trend one. No trade is admissible regardless of the chart: qualitativeScore 2 is below the required floor of 3 (and the SHADOW_FST9 flag is false), the 20-day average dollar volume of $4,430,673 is under the $5,000,000 liquidity floor, and a confirmed Q3 2026 earnings date on 2026-11-09 sits inside the 15-trading-day holding window (horizon 2026-11-10).
You’re looking at 2026-10-20 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

